

This Annex sets out the complete, sequenced list of publicly available documents identified to date relating to the review, commissioning, advice, and implementation of cannabis-based products for medicinal use (CBPMs). The table reflects verification against the underlying document content and aligns with the Home Office's two-part review structure.

Ref	Date	Document title (exact / published)	Issuing body → Recipient	Purpose / scope (as evidenced by content)	Key points relevant to regulatory architecture	Public link
A1	03-Jul-18	<i>Cannabis scheduling review: Part 1 – the therapeutic and medicinal benefits of cannabis-based products</i>	Chief Medical Officer → Home Secretary	Part 1 scientific evidence review of medicinal benefit	Concludes evidence of therapeutic benefit; Schedule 1 status for medicinal cannabis scientifically difficult to defend	<a href="https://assets.publishing.service.gov.uk/media/5b3b87ffed915d33df1edd71/CMO_Report_Cannabis_Products_Web_Accessible.pdf">https://assets.publishing.service.gov.uk/media/5b3b87ffed915d33df1edd71/CMO_Report_Cannabis_Products_Web_Accessible.pdf</a>
A2	03-Jul-18	<i>FINAL_-03_07-2018-ACMD_Commission_-DAU</i>	Home Office → ACMD	Part 2 commission following CMO review; advice on scheduling under MDR 2001	Commissions ACMD on regulatory implementation; explicitly excludes MDA 1971 matters (classification, offences, cultivation)	<a href="https://www.gov.uk/government/publications/commission-to-the-acmd-scheduling-under-the-misuse-of-drugs-regulations-2001">https://www.gov.uk/government/publications/commission-to-the-acmd-scheduling-under-the-misuse-of-drugs-regulations-2001</a>
A3	19-Jul-18	<i>Scheduling of Cannabis-Derived Medicinal Products: Advice by the ACMD</i>	ACMD → Home Office	Short-term advice under July 2018 commission	Recommends defined CBPMs move to Schedule 2; states CBPMs should not be administered by smoking	<a href="https://assets.publishing.service.gov.uk/media/5b50951ded915d43747aaa04/ACMD_advice_on_scheduling_of_cannabis_derived_medicinal_products.pdf">https://assets.publishing.service.gov.uk/media/5b50951ded915d43747aaa04/ACMD_advice_on_scheduling_of_cannabis_derived_medicinal_products.pdf</a>
A4	26-Jul-18	<i>Government response to the ACMD – cannabis-derived medicinal products</i>	Home Office → ACMD	Initial response to ACMD short-term advice	Accepts recommendations in principle; signals forthcoming legislative change	<a href="https://www.gov.uk/government/publications/government-response-to-the-acmd-cannabis-derived-medicinal-products">https://www.gov.uk/government/publications/government-response-to-the-acmd-cannabis-derived-medicinal-products</a> <a href="https://assets.publishing.service.gov.uk/media/5b97a0ded915d665d860037/Consultation_on_Cannabis-derived_medicinal_products.pdf">https://assets.publishing.service.gov.uk/media/5b97a0ded915d665d860037/Consultation_on_Cannabis-derived_medicinal_products.pdf</a>
A5	11-Sep-18	<i>Consultation on cannabis-derived medicinal products – ACMD letter</i>	ACMD → Home Office	Response to consultation on proposed implementation	Discusses implementation and route-of-administration issues	<a href="https://www.gov.uk/government/publications/response-to-acmd-cannabis-derived-medicinal-products-21-september-2018">https://www.gov.uk/government/publications/response-to-acmd-cannabis-derived-medicinal-products-21-september-2018</a>
A6	21-Sep-18	<i>Final cleared Government response to ACMD advice</i>	Home Office / Secretary of State for Health → ACMD	Definitive ministerial response following further ACMD advice	Confirms smoking prohibition will be embedded in amendments to MDR 2001	
A7	01-Nov-18	<i>Misuse of Drugs (Amendments) Regulations 2018 (SI 2018/1055)</i>	UK Government	Legislative implementation of CBPM rescheduling	Introduces CBPM definition; inserts Regulation 16A(3); criminal consequences flow from design	<a href="https://www.legislation.gov.uk/uksi/2018/1055/contents">https://www.legislation.gov.uk/uksi/2018/1055/contents</a>
A8	11-Oct-18	<i>Rescheduling of cannabis-based products for medicinal use (HCWS994; Lords equivalent HLWS961)</i>	Home Office Minister → UK Parliament	Written Ministerial Statement accompanying laying of SI	Explicitly sets out criminal-law consequences of Regulation 16A(3) for prescribed CBPM patients	<a href="https://questions-statements.parliament.uk/written-statements/detail/2018-10-11/hcws994">https://questions-statements.parliament.uk/written-statements/detail/2018-10-11/hcws994</a>
A9	Nov-18	<i>Home Office Circular 018/2018 – Cannabis-based products for medicinal use in humans</i>	Home Office → Police forces & CJS stakeholders	Operational and implementation guidance	High-level guidance on legal changes; no detailed assessment of patient criminal liability under Regulation 16A(3); no patient-facing route-breach guidance	<a href="https://www.gov.uk/government/publications/circular-0182018-rescheduling-of-cannabis-based-products-for-medicinal-use-in-humans">https://www.gov.uk/government/publications/circular-0182018-rescheduling-of-cannabis-based-products-for-medicinal-use-in-humans</a>
A10	05-Feb-19	<i>Cannabis-based products for medicinal use in humans: commission to the ACMD</i>	Home Office → ACMD	Long-term continuation of July 2018 commission	Explicitly prohibits ACMD from reviewing classification, criminal offences, or cultivation	<a href="https://assets.publishing.service.gov.uk/media/5c66ef59e5274a72be398ed1/Long-term_commission_to_the_ACMD_on_CBPM_-05_02_2019.pdf">https://assets.publishing.service.gov.uk/media/5c66ef59e5274a72be398ed1/Long-term_commission_to_the_ACMD_on_CBPM_-05_02_2019.pdf</a>
A11	23-Dec-19	<i>ACMD framework for the assessment of the impact of rescheduling CBPMs</i>	ACMD	Methodological framework for impact assessment	Defines metrics and data sources; operates within constrained remit	<a href="https://www.gov.uk/government/publications/cannabis-based-products-for-medicinal-use-in-humans-cbpm">https://www.gov.uk/government/publications/cannabis-based-products-for-medicinal-use-in-humans-cbpm</a>
A12	27-Nov-20	<i>ACMD advice on CBPM scheduling</i>	ACMD → Home Office	Advice following impact assessment	Recommends no change to CBPM scheduling	<a href="https://www.gov.uk/government/publications/cannabis-based-products-for-medicinal-use-in-humans-cbpm">https://www.gov.uk/government/publications/cannabis-based-products-for-medicinal-use-in-humans-cbpm</a>
A13	27-Nov-20	<i>Cannabis-based products for medicinal use (CBPMs): assessment report</i>	ACMD	Published impact report	Reviews prescribing, access, markets, research; does not revisit criminal architecture	<a href="https://www.gov.uk/government/publications/cannabis-based-products-for-medicinal-use-in-humans-cbpm">https://www.gov.uk/government/publications/cannabis-based-products-for-medicinal-use-in-humans-cbpm</a>
A14	01-Nov-18	<i>Explanatory Memorandum to SI 2018/1055</i>	Home Office → Parliament	Explains legal basis, policy intent, and implementation	Cites s31(1)(a) MDA; later clarification required re s7(1)(b); blends legal mechanics with policy constraints	<a href="https://www.legislation.gov.uk/uksi/2018/1055/pdfs/uksiem_20181055_en.pdf">https://www.legislation.gov.uk/uksi/2018/1055/pdfs/uksiem_20181055_en.pdf</a>
A15	01-Nov-18	<i>Impact Assessment: Rescheduling of cannabis-based products for medicinal use</i>	Home Office	Impact assessment accompanying SI	Limited analysis of criminal exposure for prescribed patients; emphasis on access and diversion narrative	<a href="https://www.legislation.gov.uk/uksi/2018/1055/impacts">https://www.legislation.gov.uk/uksi/2018/1055/impacts</a>

## Clarification

Part 1 of the review was conducted by the Chief Medical Officer, not ACMD.

The 03 July 2018 Home Office commission to ACMD is inherently Part 2 of the review.

Exclusions relating to criminal law and classification were present from the outset and later reinforced in February 2019.

No additional publicly available commissioning or correspondence documents altering this scope have been identified.